MEM-288 (solid tumors)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Take the study drug (MEM-288)
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and MRI)
- Have heart tests (ECG)
- Take the study drug (MEM-288)
- Provide tumor tissue
- Have physical exams, blood draws, and give urine samples
- Have imaging scans (CT and MRI)
- Have heart tests (ECG)
What is the Condition Being Studied?
Advanced Solid Tumors
Who Can Participate in this Study?
Adults diagnosed with the following cancers that have spread:
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous-cell carcinoma (cSCC)
- Merkel cell carcinoma
- Melanoma
- Triple negative breast cancer (TNBC)
- Pancreatic cancer
- Head and neck cancer
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out if an experimental drug called MEM-288 (the study drug) is a safe and effective treatment for your cancer.
Study Details
Full Title
Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator
Contacts
Center for Cancer Immunotherapy DCI Clinical Research Team
Phone: +1 919-681-6468
Protocol Number
IRB:
PRO00109517
NCT:
NCT05076760
ClinicalTrials.gov
View on ClinicalTrials.gov